This research study is studying several investigational drugs as a possible treatment for Glioblastoma (GBM). The drugs involved in this study are : - Abemaciclib - Temozolomide (temodar) - Neratinib - CC115
Name: Temozolomide
Description: Temzolomide capsulesType: DrugTemozolomide Abemaciclib with Temozolomide Neratinib with Temozolomide
Name: Neratinib
Description: Neratinib tabletsType: DrugNeratinib with Temozolomide
Name: CC-115
Description: CC-115 capsuleType: DrugCC-115
Name: Abemaciclib
Description: Abemaciclib capsulesType: DrugAbemaciclib with Temozolomide
Description: Safety will be assessed by quantifying the toxicities and grades experienced by subjects, including serious adverse events (SAEs). The following will also be measured as part of safety: laboratory safety assessments, KPS status, vital signs and physical examinations.
Measure: Incidence of Treatment-Emergent Adverse Events Time: 2 yearsAllocation: Randomized
Parallel Assignment
There is one SNP
- Immunohistochemically negative for IDH1 R132H mutation. --- R132H ---